UK-based specialist pharmaceutical company Acacia Pharma has reported a positive outcome from the Phase III trial of BAREMSIS to treat post-operative nausea and vomiting (PONV).

Formerly known as APD421, BAREMSIS is an intravenous formulation of amisulpride that acts as a selective dopamine antagonist.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The Phase III trial involved 568 patients suffering from nausea or vomiting post surgery and had not received any prophylactic antiemetics.

It was primarily focused to achieve a successful resolution of the episode of PONV within the 24-hour period after treatment, meaning patients will not experience a recurrence of vomiting or need further antiemetic rescue.

"We are delighted with this data demonstrating that BAREMSIS is safe and effective at treating patients suffering PONV after surgery."

Results suggested that both doses of BAREMSIS brought a significant improvement in the complete response rate when compared to placebo with the magnitude of effect remaining consistent with previous trial results.

Acacia Pharma CEO Dr Julian Gilbert said: "We are delighted with this data demonstrating that BAREMSIS is safe and effective at treating patients suffering PONV after surgery.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“It confirms our confidence in the dopamine antiemetic mechanism of action, and that BAREMSIS is effective at treating, as well as preventing, PONV.

“Our objective is to seek approval for BAREMSIS for the treatment and prophylaxis of PONV alone and in combination, which will provide us with a broad and unique label once approved.

“No other antiemetic has a PONV treatment claim following failed prophylaxis with standard antiemetics, and no other antiemetic has a combination use claim in PONV prophylaxis."

The company is currently conducting the second pivotal Phase III study of BAREMSIS, which is treating surgical patients with PONV symptoms despite receiving prior prophylaxis.